RxDoctor Payments Data

Guilford Hurst

Psychiatric/Mental Health, Adult · Lewes, DENPI 1467779256

Payments from drug & device makers

$42,255in general payments, 2019–2025

Across 316 payments — averaging $133.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$34K
  • AbbVie$5K
  • Otsuka America Pharmaceutical, Inc.$561
  • Johnson & Johnson$487
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$475
  • Avanir Pharmaceuticals, Inc.$340
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$4,38010%
  • Speaking & faculty fees$29,09569%
  • Travel & lodging$2,7156%
  • Food & beverage$6,06614%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few psychiatric/mental health, adult providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$335,010
Medicare patients
438
Services billed
3,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole71$147,036
LybalviOlanzapine/Samidorphan Malate82$144,967
IngrezzaValbenazine Tosylate16$135,435
Invega SustennaPaliperidone Palmitate39$106,434
AustedoDeutetrabenazine11$42,440
AristadaAripiprazole Lauroxil13$31,141
VraylarCariprazine Hcl19$30,640
Lupron DepotLeuprolide Acetate13$27,456
TrintellixVortioxetine Hydrobromide17$18,012
Divalproex Sodium ErDivalproex Sodium163$15,016
Aripiprazole171$14,245
Chlorpromazine Hcl18$13,481
VyvanseLisdexamfetamine Dimesylate31$11,842
Lurasidone Hcl24$11,299
Ziprasidone Hcl51$8,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Lybalvi, Aristada$34,083$176,10895 claims
Otsuka America Pharmaceutical, Inc.Rexulti$561$147,03671 claims
Neurocrine Biosciences, Inc.Ingrezza$210$135,43516 claims
Johnson & JohnsonInvega Sustenna$487$106,43439 claims
AbbVieVraylar, Lupron Depot$4,929$58,09632 claims
Teva Pharmaceuticals USA, Inc.Austedo$314$42,44011 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$262$29,85448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other psychiatric/mental health, adult in Lewes

Where these figures come from

Is this you, or does something look wrong? →